Advances in radiotherapy for lung cancer.
The past decade has seen steady advances in the field of radiation therapy, impacting definitive treatment options for early and advanced tumors, as well as identifying further roles for adjuvant and palliative therapy. The widespread availability of (18)F-fluoro-2-deoxy-D-glucose positron emission tomographic (FDG PET) imaging has improved staging, and better defines a population that will benefit from aggressive local therapy. Technological advances in radiation treatment planning allow for less normal lung irradiation, allowing increasing dose and decreasing normal tissue toxicity. Ongoing clinical investigations in the role of radiosurgery for early lung tumors, postoperative radiation of locally advanced non-small-cell lung cancer (NSCLC), and prophylactic cranial irradiation in small-cell lung cancer (SCLC) help to identify patients who may benefit from treatment.
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520-8040, USA. Roy.Decker@Yale.edu
Roy H
RH
Decker
Lynn D
LD
Wilson
D001932:Brain Neoplasms / Q000517:prevention & control / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D009364:Neoplasm Recurrence, Local; D011182:Postoperative Care / Q000379:methods; D016634:Radiosurgery; D011878:Radiotherapy / Q000379:methods; D012074:Remission Induction; D016896:Treatment Outcome